{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T21:40:19Z","timestamp":1721425219972},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00059-019-4822-7","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T13:09:34Z","timestamp":1560776974000},"page":"95-104","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Everolimus- vs. novolimus-eluting bioresorbable scaffolds in patients with acute coronary syndrome","Everolimus- vs. Novolimus-freisetzende bioresorbierbare Scaffolds bei Patienten mit akutem Koronarsyndrom"],"prefix":"10.1007","volume":"45","author":[{"given":"H. M.","family":"Nef","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wiebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"M\u00f6llmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. F.","family":"Boeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"D\u00f6rr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Blachutzik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Liebetrau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Els\u00e4sser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Foin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. W.","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,17]]},"reference":[{"issue":"23","key":"4822_CR1","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1016\/j.jacc.2014.09.041","volume":"64","author":"J Wiebe","year":"2014","unstructured":"Wiebe J, Nef HM, Hamm CW (2014) Current status of bioresorbable scaffolds in the treatment of coronary artery disease. J\u00a0Am Coll Cardiol 64(23):2541\u20132551. https:\/\/doi.org\/10.1016\/j.jacc.2014.09.041","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"4822_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1161\/CIRCULATIONAHA.117.031843","volume":"137","author":"ZA Ali","year":"2018","unstructured":"Ali ZA, Gao R, Kimura T et al (2018) Three-year outcomes with the absorb bioresorbable scaffold: individual-patient-data Meta-analysis from the ABSORB randomized trials. Circulation 137(5):464\u2013479. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.031843","journal-title":"Circulation"},{"issue":"10018","key":"4822_CR3","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0140-6736(15)00979-4","volume":"387","author":"S Cassese","year":"2016","unstructured":"Cassese S, Byrne RA, Ndrepepa G et al (2016) Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a\u00a0meta-analysis of randomised controlled trials. Lancet 387(10018):537\u2013544. https:\/\/doi.org\/10.1016\/S0140-6736(15)00979-4","journal-title":"Lancet"},{"key":"4822_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ijcard.2016.11.033","volume":"227","author":"HM Nef","year":"2017","unstructured":"Nef HM, Wiebe J, Foin N et al (2017) A new novolimus-eluting bioresorbable coronary scaffold: present status and future clinical perspectives. Int J Cardiol 227:127\u2013133. https:\/\/doi.org\/10.1016\/j.ijcard.2016.11.033","journal-title":"Int J Cardiol"},{"key":"4822_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.08.322","author":"J Costa","year":"2012","unstructured":"Costa J, Ormiston J, Abizaid A et al (2012) TCT-298 six-month Intravascular ultrasound analysis of the DEsolve FIM trial with a\u00a0novel PLLA-based fully biodegradable drug-eluting scaffold. J\u00a0Am Coll Cardiol 60(17_S). https:\/\/doi.org\/10.1016\/j.jacc.2012.08.322","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"4822_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jcin.2015.12.004","volume":"9","author":"A Abizaid","year":"2016","unstructured":"Abizaid A, Costa RA, Schofer J et al (2016) Serial Multimodality imaging and 2\u2011year clinical outcomes of the novel DEsolve novolimus-eluting bioresorbable coronary scaffold system for the treatment of single de novo coronary lesions. JACC Cardiovasc Interv 9(6):565\u2013574. https:\/\/doi.org\/10.1016\/j.jcin.2015.12.004","journal-title":"JACC Cardiovasc. Interv."},{"issue":"2","key":"4822_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/eurheartj\/ehy710","volume":"40","author":"RA Byrne","year":"2019","unstructured":"Byrne RA, Alfonso F, Schneider S et al (2019) Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a\u00a0Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial. Eur Heart\u00a0J 40(2):167\u2013176. https:\/\/doi.org\/10.1093\/eurheartj\/ehy710","journal-title":"Eur Heart J"},{"issue":"17","key":"4822_CR8","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R et al (2007) Clinical end points in coronary stent trials: a\u00a0case for standardized definitions. Circulation 115(17):2344\u20132351. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.685313","journal-title":"Circulation"},{"issue":"1","key":"4822_CR9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2011.12.008","volume":"221","author":"S Brugaletta","year":"2012","unstructured":"Brugaletta S, Radu MD, Garcia-Garcia HM et al (2012) Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis 221(1):106\u2013112. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.12.008","journal-title":"Atherosclerosis"},{"issue":"7","key":"4822_CR10","doi-asserted-by":"publisher","first-page":"746","DOI":"10.4244\/EIJY14M10_06","volume":"11","author":"CV Bourantas","year":"2015","unstructured":"Bourantas CV, Serruys PW, Nakatani S et al (2015) Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a\u00a0concept based on serial optical coherence tomography data. EuroIntervention 11(7):746\u2013756. https:\/\/doi.org\/10.4244\/EIJY14M10_06","journal-title":"EuroIntervention"},{"issue":"4","key":"4822_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.4244\/EIJV9I4A80","volume":"9","author":"T Kajiya","year":"2013","unstructured":"Kajiya T, Liang M, Sharma RK et al (2013) Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI). EuroIntervention 9(4):501\u2013504. https:\/\/doi.org\/10.4244\/EIJV9I4A80","journal-title":"EuroIntervention"},{"issue":"6","key":"4822_CR12","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jcin.2014.12.244","volume":"8","author":"T Gori","year":"2015","unstructured":"Gori T, Schulz E, Hink U et al (2015) Clinical, angiographic, functional, and imaging outcomes 12 months after implantation of drug-eluting bioresorbable vascular scaffolds in acute coronary syndromes. JACC Cardiovasc Interv 8(6):770\u2013777. https:\/\/doi.org\/10.1016\/j.jcin.2014.12.244","journal-title":"JACC Cardiovasc. Interv."},{"issue":"12","key":"4822_CR13","doi-asserted-by":"crossref","first-page":"669","DOI":"10.20452\/pamw.2550","volume":"124","author":"D Dudek","year":"2014","unstructured":"Dudek D (2014) Bioresorbable vascular scaffolds in patients with acute coronary syndromes: the POLAR ACS study. Pol Arch Med Wewn 124(12):669\u2013677","journal-title":"Pol Arch Med Wewn"},{"issue":"12","key":"4822_CR14","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/eurheartj\/eht545","volume":"35","author":"V Kocka","year":"2014","unstructured":"Kocka V, Maly M, Tousek P et al (2014) Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a\u00a0prospective multicentre study \u2018Prague 19. Eur Heart\u00a0J 35(12):787\u2013794. https:\/\/doi.org\/10.1093\/eurheartj\/eht545","journal-title":"Eur Heart J"},{"issue":"2","key":"4822_CR15","first-page":"125","volume":"56","author":"A Karanasos","year":"2015","unstructured":"Karanasos A, Muramatsu T, Diletti R et al (2015) Early and late optical coherence tomography findings following everolimus-eluting bioresorbable vascular scaffold implantation in myocardial infarction: a\u00a0preliminary report. Hellenic J Cardiol 56(2):125\u2013135","journal-title":"Hellenic J Cardiol"},{"issue":"1","key":"4822_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4244\/EIJY15M02_03","volume":"11","author":"JA Ormiston","year":"2015","unstructured":"Ormiston JA, Webber B, Ubod B, Darremont O, Webster MW (2015) An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a\u00a0durable metallic drug-eluting stent (ML8\/Xpedition). EuroIntervention 11(1):60\u201367. https:\/\/doi.org\/10.4244\/EIJY15M02_03","journal-title":"EuroIntervention"},{"issue":"6","key":"4822_CR17","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/ccd.27550","volume":"92","author":"H Nef","year":"2018","unstructured":"Nef H, Wiebe J, Boeder N et al (2018) A multicenter post-marketing evaluation of the Elixir DESolve((R)) Novolimus-eluting bioresorbable coronary scaffold system: First results from the DESolve PMCF study. Catheter Cardiovasc Interv 92(6):1021\u20131027. https:\/\/doi.org\/10.1002\/ccd.27550","journal-title":"Catheter Cardiovasc Interv"},{"issue":"11","key":"4822_CR18","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.4244\/EIJ-D-17-00330","volume":"13","author":"HM Nef","year":"2017","unstructured":"Nef HM, Wiebe J, Kastner J et al (2017) Everolimus-eluting bioresorbable scaffolds in patients with coronary artery disease: results from the German-Austrian ABSORB RegIstRy (GABI-R). EuroIntervention 13(11):1311\u20131318. https:\/\/doi.org\/10.4244\/EIJ-D-17-00330","journal-title":"EuroIntervention"},{"issue":"20","key":"4822_CR19","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa1509038","volume":"373","author":"SG Ellis","year":"2015","unstructured":"Ellis SG, Kereiakes DJ, Metzger DC et al (2015) Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N\u00a0Engl J Med 373(20):1905\u20131915. https:\/\/doi.org\/10.1056\/NEJMoa1509038","journal-title":"N Engl J Med"},{"issue":"1","key":"4822_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jcin.2007.10.005","volume":"1","author":"E Romagnoli","year":"2008","unstructured":"Romagnoli E, Sangiorgi GM, Cosgrave J, Guillet E, Colombo A (2008) Drug-eluting stenting: the case for post-dilation. JACC Cardiovasc Interv 1(1):22\u201331. https:\/\/doi.org\/10.1016\/j.jcin.2007.10.005","journal-title":"JACC Cardiovasc. Interv."},{"issue":"15","key":"4822_CR21","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1093\/eurheartj\/ehv711","volume":"37","author":"G Souteyrand","year":"2016","unstructured":"Souteyrand G, Amabile N, Mangin L et al (2016) Mechanisms of stent thrombosis analysed by optical coherence tomography: insights from the national PESTO French registry. Eur Heart\u00a0J 37(15):1208\u20131216. https:\/\/doi.org\/10.1093\/eurheartj\/ehv711","journal-title":"Eur Heart J"},{"key":"4822_CR22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.114.002369","author":"A Karanasos","year":"2015","unstructured":"Karanasos A, Van Mieghem N, van Ditzhuijzen N et al (2015) Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience. Circ Cardiovasc Interv. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.114.002369","journal-title":"Circ Cardiovasc Interv"},{"issue":"1","key":"4822_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4244\/EIJV12I1A6","volume":"12","author":"JM Fam","year":"2016","unstructured":"Fam JM, Felix C, van Geuns RJ et al (2016) Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a\u00a0propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study. EuroIntervention 12(1):30\u201337. https:\/\/doi.org\/10.4244\/EIJV12I1A6","journal-title":"EuroIntervention"},{"issue":"1","key":"4822_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4244\/EIJY15M01_05","volume":"11","author":"C Tamburino","year":"2015","unstructured":"Tamburino C, Latib A, van Geuns RJ et al (2015) Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a\u00a0European perspective. EuroIntervention 11(1):45\u201352. https:\/\/doi.org\/10.4244\/EIJY15M01_05","journal-title":"EuroIntervention"},{"issue":"8","key":"4822_CR25","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jacc.2015.12.019","volume":"67","author":"S Puricel","year":"2016","unstructured":"Puricel S, Cuculi F, Weissner M et al (2016) Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors. J\u00a0Am Coll Cardiol 67(8):921\u2013931. https:\/\/doi.org\/10.1016\/j.jacc.2015.12.019","journal-title":"J Am Coll Cardiol"},{"issue":"1 Pt B","key":"4822_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jcin.2014.10.005","volume":"8","author":"S Brugaletta","year":"2015","unstructured":"Brugaletta S, Gori T, Low AF et al (2015) Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1\u2011year results of a\u00a0propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). JACC Cardiovasc Interv 8(1 Pt B):189\u2013197. https:\/\/doi.org\/10.1016\/j.jcin.2014.10.005","journal-title":"JACC Cardiovasc. Interv."},{"issue":"3","key":"4822_CR27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/eurheartj\/ehv500","volume":"37","author":"M Sabate","year":"2016","unstructured":"Sabate M, Windecker S, Iniguez A et al (2016) Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart\u00a0J 37(3):229\u2013240. https:\/\/doi.org\/10.1093\/eurheartj\/ehv500","journal-title":"Eur Heart J"},{"key":"4822_CR28","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-18-01080","author":"S Cassese","year":"2019","unstructured":"Cassese S, Katagiri Y, Byrne RA et al (2019) Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents. A pooled analysis of individual patient data from 2 randomized trials. EuroIntervention. https:\/\/doi.org\/10.4244\/EIJ-D-18-01080","journal-title":"EuroIntervention"},{"issue":"3","key":"4822_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12471-015-0651-3","volume":"23","author":"B Everaert","year":"2015","unstructured":"Everaert B, Felix C, Koolen J et al (2015) Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a\u00a0recommendation from experienced users : A position statement on the use of bioresorbable vascular scaffolds in the Netherlands. Neth Heart\u00a0J 23(3):161\u2013165. https:\/\/doi.org\/10.1007\/s12471-015-0651-3","journal-title":"Neth Heart J"},{"issue":"10","key":"4822_CR30","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.4244\/EIJV10I10A190","volume":"10","author":"UK Allahwala","year":"2015","unstructured":"Allahwala UK, Cockburn JA, Shaw E et al (2015) Clinical utility of optical coherence tomography (OCT) in the optimisation of Absorb bioresorbable vascular scaffold deployment during percutaneous coronary intervention. EuroIntervention 10(10):1154\u20131159. https:\/\/doi.org\/10.4244\/EIJV10I10A190","journal-title":"EuroIntervention"},{"issue":"2","key":"4822_CR31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"FJ Neumann","year":"2019","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A et al (2019) 2018 ESC\/EACTS Guidelines on myocardial revascularization. Eur Heart\u00a0J 40(2):87\u2013165. https:\/\/doi.org\/10.1093\/eurheartj\/ehy394","journal-title":"Eur Heart J"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-019-4822-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-019-4822-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-019-4822-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T21:09:54Z","timestamp":1721423394000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-019-4822-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,17]]},"references-count":31,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4822"],"URL":"https:\/\/doi.org\/10.1007\/s00059-019-4822-7","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,17]]},"assertion":[{"value":"28 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"H.\u00a0M\u00f6llmann and C.W.\u00a0Hamm received speaker\u2019s fees from Abbott Vascular. H.M.\u00a0Nef received speaker\u2019s fees from Abbott Vascular and Elixir Medical and institutional research grants from Abbott Vascular and Elixir Medical. J.\u00a0Wiebe, G.\u00a0Schmidt, N.F.\u00a0Boeder, O.\u00a0D\u00f6rr, T.\u00a0Bauer, F.\u00a0Blachutzik, C.\u00a0Liebetrau, A.\u00a0Els\u00e4sser, and N.\u00a0Foin declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}